FACTOR VIII (ANTI- HEMOPHILIA A) ACTIVITY

The FACTOR VIII (ANTI-HEMOPHILIA A) ACTIVITY test is a specialized coagulation assay used to measure the level and functional activity of Factor VIII, an essential blood clotting protein. Factor VIII plays a critical role in the intrinsic pathway of the coagulation cascade and is necessary for normal blood clot formation.

A deficiency or dysfunction of Factor VIII leads to a genetic bleeding disorder known as Hemophilia A, one of the most common inherited clotting disorders. This test helps in diagnosing Hemophilia A, determining its severity, and monitoring treatment effectiveness.

The test measures how efficiently Factor VIII functions in plasma and is an important part of advanced hematology and coagulation evaluation.

Benefits of the Test

• Diagnoses Hemophilia A (Factor VIII deficiency)
• Evaluates severity of bleeding disorders
• Helps guide clotting factor replacement therapy
• Assesses unexplained prolonged bleeding
• Supports pre-surgical risk assessment
• Monitors response to treatment in hemophilia patients

Why Doctors Recommend This Test

Doctors recommend the Factor VIII activity test when patients experience excessive bleeding, spontaneous joint or muscle bleeding, prolonged bleeding after injury or surgery, or unexplained bruising. It is also recommended for individuals with a family history of hemophilia or abnormal coagulation screening results.

This test is essential for confirming Hemophilia A and planning long-term management.

Preparation Before Test

• No fasting required
• Inform doctor about anticoagulant medications
• Share family history of bleeding disorders
• Do not stop any medication without medical advice
• Blood sample is collected under standard laboratory conditions

Normal Reporting Time

Results are typically available within 24 to 48 hours, depending on laboratory processing.

Who Should Take This Test

• Patients with unexplained or excessive bleeding
• Suspected Hemophilia A cases
• Individuals with prolonged bleeding after injury
• Pre-surgical coagulation screening patients
• Patients with family history of hemophilia
• Individuals with joint or muscle bleeding episodes